The overall aim of the project is to gain increased knowledge of the stem cell nishe in glioblastoma. By adapting a proteogenomics approach, we aim to detect specific features of this therapy resistant cell population by comparison between primary human glioblastoma cell lines, glioblastoma cell lines and normal astrocytes.
We will receive BAM-files containing data from RNA sequencing analysis of human primary glioma stem cell lines. The primary stem cell lines have been sequenced by our collaborators at University of Rome Tor Vergata, Italy, and we will perform the corresponding proteogenomics analysis. Since the RNA sequencing data is derived from from human donors we are in need of space for handling sensitive data.
In total RNA sequencing data from 7 donors will be analysed, to call for variants and create samples specific databases for the corresponding mass spectrometry analysis of the protein sequencing.